



**FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY**

**EMBARGOED: NOT FOR PUBLICATION BEFORE 09.00AM GMT ON XX NOV 2018**

## **Mundipharma announces Marco Cerato as Senior Vice President Business Development and Strategic Partnerships**

- Marco brings over a decade's experience in pharmaceutical business development
- Previously, Marco was Global Head, Business Development and Licensing at Helsinn Healthcare

**Cambridge, UK, X November 2018** – The Mundipharma network of independent associated companies today confirmed the appointment of Marco Cerato, who joins the European team as Senior Vice President Business Development and Strategic Partnerships, reporting to Alberto Martinez, President & Chief Executive Officer in Europe.

Marco brings with him a wealth of business development experience, namely in-licensing, out-licensing, alliance management and mergers & acquisitions globally, with a specific focus on cancer supportive care and oncology. He started his career with Eurand in Italy and since 2011 has been at Helsinn Healthcare in Switzerland, where his last role was Global Head, Business Development and Licensing.

Commenting on his appointment, Marco said: "It's an exciting time to be joining Mundipharma as it increases its focus on delivering innovation through partnerships, my position is crucial to making this vision a reality. At Helsinn I oversaw more than 50 licensing deals covering more than 190 countries around the world for five different assets in cancer supportive care and oncology. I'm hoping to replicate some of that success here at Mundipharma."

Alberto Martinez, President & Chief Executive Officer added: "We are delighted to fill this strategic position with such a motivated individual. Marco has significant commercial, development and strategic leadership expertise. Marco will be responsible for our European business development team and strategy as well as for coordinating our internal and external partnerships in order to enhance our product portfolio and pipeline."



**FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY**

**Notes to editors:**

**About the Mundipharma network**

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don't by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.

For more information please visit: [www.mundipharma.com](http://www.mundipharma.com)

**For further information please contact:**

Alison Dyson

[Alison.dyson@mundipharma.com](mailto:Alison.dyson@mundipharma.com)

T: +44 (0) 1223 397 346

Helen Rae

[Helenrae@makarahealth.com](mailto:Helenrae@makarahealth.com)

T: +44 (0) 23 81 247 327